Neuronetics, Inc. — fact timeline

Nir Naor was appointed as principal financial and accounting officer and corporate secretary at Neuronetics, Inc..

“On August 12, 2026, the Board appointed Mr. Naor to serve as the Company’s principal financial and accounting officer.”

Francis X. Brown III departed as interim principal financial and accounting officer at Neuronetics, Inc..

“On August 11, 2026, in connection with Mr. Naor’s appointment (as described below), Francis X. Brown III’s appointment as Neuronetics, Inc.’s (the “Company”) interim principal financial and accounting officer ended.”

Nir Naor was appointed as Executive Vice President, Chief Financial Officer, and Treasurer at Neuronetics, Inc..

“On July 9, 2026, the Board appointed Nir Naor as the Company’s Executive Vice President, Chief Financial Officer, and Treasurer with an effective date on or about July 23, 2026.”

W. Andrew Macan resigned as Executive Vice President, Chief Legal Officer, and Corporate Secretary at Neuronetics, Inc..

“On July 17, 2026, Neuronetics, Inc. (the “Company”) and W. Andrew Macan, who has served as Executive Vice President, Chief Legal Officer, and Corporate Secretary and in various other similar capacities since January 21, 2020, entered into a Separation Agreement (the “Separation Agreement”).”

Cory Anderson changed role as Executive Vice President, General Manager of Greenbrook at Neuronetics, Inc..

“On June 16, 2026, the board of directors of the Company (the “Board”) promoted Cory Anderson from the position of Senior Vice President, Chief Technology Officer to the position of Executive Vice President, General Manager of Greenbrook effective July 1, 2026.”

Neuronetics, Inc. shareholders approved Approval of Neuronetics, Inc. 2026 Equity Incentive Plan at the 2026-05-28 meeting.

“Proposal 4: The approval of the Neuronetics, Inc. 2026 Equity Incentive Plan was approved by the Company’s stockholders by the votes set forth in the table below: 23,802,955 votes FOR the proposal 16,651,661 votes AGAINST the proposal 833,908 votes ABSTAIN 14,661,594 votes Broker Non-Votes”

Neuronetics, Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2026-05-28 meeting.

“Proposal 3: The approval, on a non-binding, advisory basis, of the compensation of the individual who served as our principal executive officer during 2025 and our two other most highly compensated executive officers who were serving as executive officers as of December 31, 2025 was ratified by the Company’s stockholders by the votes set forth in the table below: 29,133,360 votes FOR the proposal 11,503,294 votes AGAINST the proposal 651,870 votes ABSTAIN 14,661,594 votes Broker Non-Votes”

Neuronetics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-05-28 meeting.

“Proposal 2: The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by the Company’s stockholders by the votes set forth in the table below: 47,194,967 votes FOR the proposal 6,924,816 votes AGAINST the proposal 1,830,335 votes ABSTAIN”

Neuronetics, Inc. shareholders approved Election of directors at the 2026-05-28 meeting.

“Proposal 1: All of the nominees for director were elected to serve a one-year term until the 2027 Annual Meeting, or until their respective successors are elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes Avinash N. Amin, M.D. 33,982,534 7,305,990 14,661,594 Robert A. Cascella 29,304,597 11,983,927 14,661,594 Sheryl L. Conley 29,304,311 11,984,213 14,661,594 Sasha S. Cucuz 28,512,554 12,775,970 14,661,594 Glenn P. Muir 29,281,048 12,007,476 14,661,594 Daniel L. Reuvers 34,472,656 6,815,868 14,661,594 Megan R. Rosengarten 28,794,454 12,494,070 14,661,594”

Neuronetics, Inc. reported three months ended March 31, 2026 results: revenue $34.5 million, net income $(10.8) million, EPS $(0.16) per share. Guidance reaffirmed.

“Total revenue for the three months ended March 31, 2026 was $34.5 million, an increase of $2.5 million, or 8%, compared to the three months ended March 31, 2025 revenue of $32.0 million.”

Neuronetics, Inc. announced a restructuring with charges of approximately $0.2 million (up to 5% of its employees).

“On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort to optimize the Company’s cost structure. The Company expects to incur restructuring charges of approximately $0.2 million, primarily for severance and related costs, in the second quarter of 2026.”

Neuronetics, Inc. reported full year 2026 results: revenue $160 million and $166 million. Guidance initiated.

“Expect full year 2026 revenue of between $160 million and $166 million”

Neuronetics, Inc. reported the twelve months ended December 31, 2025 results: revenue $149.2 million.

“Full year revenue of $149.2 million, up 99% as reported and 15% on an adjusted pro forma basis as compared to the full year 2024”

Neuronetics, Inc. reported the three months ended December 31, 2025 results: revenue $41.8 million, net income $(7.2) million, EPS $(0.10) per share.

“Fourth quarter 2025 revenue of $41.8 million, up 86% as reported and 23% on an adjusted pro forma basis as compared to the fourth quarter 2024”

Neuronetics, Inc. amended Amendment No. 4 to Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP (effective 2026-01-15).

“(the “Company”) entered into a Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP, (“Perceptive”) as collateral agent and other lenders defined in the agreement (the “Perceptive Facility”).”

Stephen Furlong departed as Chief Financial Officer at Neuronetics, Inc..

“On May 6, 2025, the Company announced that Stephen Furlong, who has served as Chief Financial Officer since 2019, will retire on March 31, 2026.”

Neuronetics, Inc.: Increased board size from five to seven and appointed two new directors Sasha Cucuz and Avinash Amin, M.D (effective 2024-12-10).

“On December 10, 2024, the board of directors of the Company (the “Board”) increased the number of directors on the Board from five (5) to seven (7) and appointed Sasha Cucuz and Avinash Amin, M.D.”

Neuronetics, Inc.: Amended certificate of incorporation to increase authorized common shares from 200,000,000 to 250,000,000 (effective 2024-12-10).

“On December 10, 2024, the Company’s amended the Ninth Amended and Restated Certificate of Incorporation in connection with the Arrangement and in accordance with the terms of the Arrangement Agreement (the “Charter Amendment”). The Charter Amendment increases the number of authorized shares of Neuronetics common stock from 200,000,000 shares to 250,000,000 shares, such share authorization having been approved at the Company’s special meeting of stockholders held on November 8, 2024.”

Neuronetics, Inc. completed an acquisition involving Greenbrook TMS Inc. (closed 2024-12-09).

“(“Neuronetics” or the “Company”) with the Securities and Exchange Commission (the “SEC”), the Company entered into an Arrangement Agreement on August 11, 2024 (the “Arrangement Agreement”), with Greenbrook TMS Inc. (“Greenbrook”), pursuant to which the Company agreed to acquire all of the issued and outstanding common shares of Greenbrook (the “Greenbrook Shares”) pursuant to a plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (Ontario) (the “Arrangement”).”

Neuronetics, Inc. announced a restructuring with charges of approximately $0.4 million (approximately 10%).

“will also improve operational efficiency, with anticipated post-reorganization annualized cash savings of more than $3.5 million. The Company expects to recognize approximately $0.4 million in total expenses for severance and related benefits for employees impacted by the reduction in force, consisting primarily of severance payments and related benefits. The”

Neuronetics, Inc. reported first quarter of 2024; three months ended March 31, 2024 results: revenue $17.4 million, net income $(7.9) million, or $(0.27) per share, EPS $(0.27) per share.

“therapies in the world, today announced its financial and operating results for the first quarter of 2024. First Quarter 2024 Highlights ● First quarter 2024 revenue of $17.4 million, a 12% increase as compared to the first quarter 2023 ● U.S. treatment session revenue increased by 22% versus the first quarter of 2023 ● U.S. NeuroStar Advanced Therapy system”

Wilfred E. Jaeger departed as Director at Neuronetics, Inc..

“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”

Joseph H. Capper departed as Director at Neuronetics, Inc..

“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”

John K. Bakewell departed as Director at Neuronetics, Inc..

“Messrs. John K. Bakewell and Joseph H. Capper and Dr. Wilfred E. Jaeger advised the Company that they would not stand for reelection to the Board at the 2024 Annual Meeting.”

Neuronetics, Inc. reported three and twelve months ended December 31, 2023 results: revenue $20.3 million; $71.3 million, net income $(5.4) million; not stated for full year, EPS $(0.19) per share; not stated for full year.

“in the world, today announced its financial and operating results for the fourth quarter and full year of 2023. Fourth Quarter 2023 Highlights ● Fourth quarter 2023 revenue of $20.3 million, a 12% increase as compared to the fourth quarter 2022 ● U.S. NeuroStar Advanced Therapy system revenue of $4.5 million, in the quarter, the Company shipped 59 systems ● Achieved”

Neuronetics, Inc. reported the twelve months ended December 31, 2023 results: revenue over $71 million.

“Preliminary unaudited total revenue is expected to be over $71 million as compared to previously stated guidance of $70.0 to $72.0 million.”

Neuronetics, Inc. reported the three months ended December 31, 2023 results: revenue over $20 million.

“Preliminary unaudited total revenue is expected to be over $20 million as compared to previously stated guidance of $19.0 to $21.0 million.”

Neuronetics, Inc. reported the three months ended September 30, 2023 results: revenue $17.9 million, net income $(9.4) million, EPS $(0.33) per share.

“therapies in the world, today announced its financial and operating results for the third quarter of 2023. Third Quarter 2023 Highlights ● Third quarter 2023 revenue of $17.9 million, an increase of 8% over the third quarter of 2022 ● Record U.S. treatment session revenue of $13.1 million ● Shipped 43 NeuroStar systems ​ Recent Operational Highlights ●”

Neuronetics, Inc. incurred term loan of $22.5 million with SLR Investment Corp..

“On October 3, 2023, the Company borrowed an aggregate amount of $22.5 million under the Term C Loan portion of the Solar Facility.”

Neuronetics, Inc. amended Fifth Amendment to Loan and Security Agreement with SLR Investment Corp. valued at $22.5 million (effective 2023-09-29).

“On September 29, 2023, Neuronetics, Inc. (the “Company”) entered into that certain Fifth Amendment to Loan and Security Agreement (the “Amendment”) with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent, and the lenders listed on the signature pages thereto (the “Lenders”).”

Neuronetics, Inc. shareholders approved Ratification of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-05-25 meeting.

“Proposal 2: The appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified by the Company’s stockholders by the votes set forth in the table below: For Against Abstained 16,802,332 2,981,999 2,910”

Neuronetics, Inc. shareholders approved Election of Directors at the 2023-05-25 meeting.

“Proposal 1: All of the nominees for director were elected to serve a one-year term until the 2024 Annual Meeting, or until their respective successors are elected and qualified, by the votes set forth in the table below: Nominees For Withheld Broker Non-Votes John K. Bakewell 16,051,257 553,330 3,182,654 Joseph H. Capper 15,878,867 725,720 3,182,654 Robert A. Cascella 14,585,133 2,019,454 3,182,654 Sheryl L. Conley 9,498,105 7,106,482 3,182,654 Wilfred E. Jaeger 12,883,089 3,721,498 3,182,654 Glenn P. Muir 13,037,525 3,567,062 3,182,654 Megan Rosengarten 16,049,221 555,366 3,182,654 Keith J. Sullivan 16,040,791 563,796 3,182,654”

Neuronetics, Inc. reported the three months ended March 31, 2023 results: revenue $15.5 million, net income $(10.5) million, EPS $(0.38) per share.

“therapies in the world, today announced its financial and operating results for the first quarter of 2023. First Quarter 2023 Highlights ● First quarter 2023 revenue of $15.5 million, an increase of 10% over the first quarter of 2022 ● U.S. treatment session revenue increased 12% over the first quarter of 2022 ● Shipped 49 systems continuing our capital”

Neuronetics, Inc. incurred loan of $6,000,000 with TMS Neurohealth Centers Inc. at Daily Simple SOFR plus 7.65% per annum maturing March 31, 2027.

“On March 31, 2023, the Company entered into a Secured Promissory Note and Guaranty Agreement (the “Promissory Note”) with TMS Neurohealth Centers Inc. (the “Maker”) and Greenbrook TMS Inc. and its subsidiaries, excluding the Maker (the “Guarantors"), in the principal amount of $6,000,000.”

Neuronetics, Inc. incurred term loan of $2.5 million with SLR Investment Corp. at greater of (a) 3.95% or (b) Daily Simple SOFR for a term of one month, plus 5.65 maturing March 29, 2028.

“On March 29, 2023, the Company borrowed an aggregate amount of $2.5 million under the Term B Loan portion of the Solar Facility.”

Neuronetics, Inc. amended credit facility with SLR Investment Corp. at greater of (a) 3.95% or (b) Daily Simple SOFR for a term of one month, plus 5.65 maturing March 29, 2028.

“On March 29, 2023, Neuronetics, Inc. (the “Company”) entered into that certain Fourth Amendment to Loan and Security Agreement (the “Amendment”) with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar"), as collateral agent, and the lenders listed on the signature pages thereto (the “Lenders”).”

Neuronetics, Inc. entered into Secured Promissory Note and Guaranty Agreement with TMS Neurohealth Centers Inc. valued at $6,000,000 (effective 2023-03-31).

“On March 31, 2023, the Company entered into a Secured Promissory Note and Guaranty Agreement (the “Promissory Note”) with TMS Neurohealth Centers Inc. (the “Maker”) and Greenbrook TMS Inc. and its subsidiaries, excluding the Maker (the “Guarantors”), in the principal amount of $6,000,000.”

Neuronetics, Inc. amended Fourth Amendment to Loan and Security Agreement with SLR Investment Corp. valued at $60.0 million (effective 2023-03-29).

“On March 29, 2023, Neuronetics, Inc. (the “Company”) entered into that certain Fourth Amendment to Loan and Security Agreement (the “Amendment”) with SLR Investment Corp. (formerly known as Solar Capital Ltd.) (“Solar”), as collateral agent, and the lenders listed on the signature pages thereto (the “Lenders”).”

Neuronetics, Inc. reported the three months ended December 31, 2022 and the year ended December 31, 2022 results: revenue $65.2 million.

“of $12.5 million in the fourth quarter 2022 ● Increased NeuroStar System revenue 64% over the fourth quarter of 2021 ​ ​ Full Year 2022 Highlights ● Full year 2022 revenue of $65.2 million, representing an 18% increase as compared to full year 2021 ● Full year 2022 U.S. treatment session revenue of $45.1 million ● Full year 2022 U.S. NeuroStar Advanced Therapy”

Neuronetics, Inc.: Adopted Fourth Amended and Restated Bylaws updating provisions for universal proxy rules and making administrative changes (effective 2022-12-27).

“On December 27, 2022, the Board voted to adopt the Fourth Amended and Restated Bylaws (the “A&R Bylaws”), which became effective immediately upon adoption. The A&R Bylaws amend and restate the Company’s previously existing bylaws in their entirety to, among other things, (i) update provisions as a result of universal proxy rules adopted by the SEC with respect to the nomination of directors for election, including a requirement for a stockholder submitting a nomination notice to make a representation as to whether such stockholder intends to solicit proxies in support of director nominees other than the Company’s nominees in accordance with Rule 14a-19 under the Securities Exchange Act of 1934, as amended, and to provide reasonable evidence that certain requirements of such rule have been satisfied; and (ii) make certain other administrative, modernizing, clarifying and conforming changes.”

Joseph H. Capper was appointed as Director at Neuronetics, Inc..

“appointed Joseph H. Capper as a director and member of the Board’s Audit Committee effective January 1, 2023.”

Neuronetics, Inc. reported the three and nine months ended September 30, 2022 results: revenue $16.5 million, net income $(7.6) million, or $(0.28) per share, EPS $(0.28) per share. Guidance raised.

“therapies in the world, today announced its financial and operating results for the third quarter of 2022. Third Quarter 2022 Highlights ● Third quarter 2022 revenue of $16.5 million, represents a 20% increase as compared to the third quarter 2021 ● Achieved record quarterly U.S. treatment session revenue of $11.9 million in the third quarter 2022, compared”

Bruce J. Shook resigned as Director at Neuronetics, Inc..

“On August 22, 2022, Bruce J. Shook notified the board of directors (the “Board”) of Neuronetics, Inc. (the “Company”) of his decision to resign from the Board effective as of October 31, 2022.”

Megan Rosengarten was appointed as Director at Neuronetics, Inc..

“appointed Megan Rosengarten as a director and member of the Board’s Compensation Committee.”